Names and Identifiers

• • Eptifibatide
  • MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2
  • INTEGRELIN
  • N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
  • {MPA}{HAR}GDWPC-NH2
  • MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2
  • MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDE BRIDGE, MPA1-CYS6)
  • Intrifiban
  • 3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2
  • N6-(AMinoiMinoMethyl)-N2-(3-Mercapto-1-oxopropyl)-L-lysylglycyl-L-.alpha.-aspartyl-L-tryptophyl-L-prolyl-L-cysteinaMide Cyclic (16)-Disulfide
  • Eptifibatide impurity
  • Integrilin
  • Eptifibatide Acetate
  • C35H49N11O9S2
  • NA8320J834
  • DSSTox_RID_81810
  • DSSTox_CID_26673
  • DSSTox_GSID_46673
  • S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]
  • N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
  • [(3R,11
  • AKOS015895205
  • NCGC00167505-01
  • EPTIFIBATIDE [INN]
  • NCGC00263524-01
  • Eptifibatide Accord (generic)
  • [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
  • EX-A3111
  • GTPL6585
  • Tox21_112503_1
  • EPTIFIBATIDE (MART.)
  • N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
  • L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-
  • CHEMBL1174
  • Sch-60936
  • 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)-
  • CHEBI:291902
  • eptifibatidum
  • C73610
  • BDBM50092098
  • L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide
  • Eptifibatide [INN:BAN]
  • HY-B0686
  • EPTIFIBATIDE [ORANGE BOOK]
  • NCGC00167505-03
  • Tox21_112503
  • 188627-80-7
  • DTXCID5026673
  • C68-22
  • A-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1 inverted exclamation marku6)-disulfide
  • EPTIFIBATIDE [EMA EPAR]
  • epifibratide
  • ((3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosin-17-yl)acetic acid
  • CCG-270517
  • Q2295855
  • EPTIFIBATIDE [MI]
  • SCHEMBL15781
  • Eptifibatide acetate?
  • AKOS025147403
  • EPTIFIBATIDE [USAN]
  • EPTIFIBATIDE [VANDF]
  • 157630-07-4
  • 1-[(1R)-1-Phenylethyl]-1Himidazole-5-carboxylic acid ethyl ester; (+)-Ethyl 1-(
  • HSDB 8313
  • UNII-NA8320J834
  • CZKPOZZJODAYPZ-LROMGURASA-N
  • 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
  • EPTIFIBATIDE [MART.]
  • [22-Carbamoyl-14-(4-guanidino-butyl)-5-(1H-indol-3-ylmethyl)-4,7,10,13,16,24-hexaoxo-docosahydro-19,20-dithia-3a,6,9,12,15,23-hexaaza-cyclopentacyclotricosen-8-yl]-acetic acid (C68-22, eptifibatide)
  • L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide
  • 2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
  • B01AC16
  • Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2
  • DTXSID7046673
  • 2-[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
  • N(SUP 6)-AMIDINO-N(SUP 2)-(3-MERCAPTOPROPIONYL)-L-LYSYLGLYCYL-L-ALPHA-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-L-CYSTEINAMIDE, CYCLIC(1-6)-DISULPHIDE
  • 2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-1H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl)acetic acid
  • Eptifibatida
  • 148031-34-9
  • epifibatide
  • CAS-188627-80-7
  • HS-2011
  • L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1-->6)-disulfide
  • EPTIFIBATIDE [WHO-DD]
  • S(1),S(6)-cyclo(N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide)
  • A-methyl-benzyl)-imidazole-5-carboxylate
  • Z2241982440
  • 1248559-53-6
  • Eptifibatide，MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2，{MPA}{HAR}GDWPC-NH2
  • +expand
• • MDL： MFCD08690339
  • Inchi： 1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
  • InChI Key： CZKPOZZJODAYPZ-LROMGURASA-N
  • SMILES： S1C[C@@H](C(N)=O)NC([C@@H]2CCCN2C([C@H](CC2=CNC3C=CC=CC2=3)NC([C@H](CC(=O)O)NC(CNC([C@H](CCCC/N=C(\N)/N)NC(CCS1)=O)=O)=O)=O)=O)=O

Computed Properties

Experimental Properties